Bruker Co. (NASDAQ:BRKR) Shares Purchased by EDENTREE ASSET MANAGEMENT Ltd

EDENTREE ASSET MANAGEMENT Ltd boosted its stake in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 11.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 158,000 shares of the medical research company's stock after purchasing an additional 15,900 shares during the period. Bruker makes up about 2.7% of EDENTREE ASSET MANAGEMENT Ltd's portfolio, making the stock its 9th biggest position. EDENTREE ASSET MANAGEMENT Ltd owned approximately 0.10% of Bruker worth $9,262,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Quadrant Capital Group LLC lifted its stake in Bruker by 18.2% during the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after acquiring an additional 196 shares during the period. Insigneo Advisory Services LLC lifted its stake in Bruker by 4.7% during the 4th quarter. Insigneo Advisory Services LLC now owns 4,880 shares of the medical research company's stock valued at $286,000 after acquiring an additional 218 shares during the period. Arizona State Retirement System lifted its stake in Bruker by 0.7% during the 4th quarter. Arizona State Retirement System now owns 30,725 shares of the medical research company's stock valued at $1,801,000 after acquiring an additional 222 shares during the period. CIBC Asset Management Inc lifted its stake in Bruker by 5.6% during the 4th quarter. CIBC Asset Management Inc now owns 4,233 shares of the medical research company's stock valued at $248,000 after acquiring an additional 223 shares during the period. Finally, UMB Bank n.a. lifted its stake in Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after acquiring an additional 248 shares during the period. Hedge funds and other institutional investors own 79.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on BRKR shares. UBS Group decreased their price objective on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Stifel Nicolaus lowered their price target on shares of Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday, May 8th. Guggenheim reissued a "buy" rating on shares of Bruker in a report on Monday, February 24th. Wells Fargo & Company lowered their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a report on Thursday, April 17th. Finally, The Goldman Sachs Group lowered their price target on shares of Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a report on Thursday, May 8th. Six research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Bruker currently has an average rating of "Hold" and a consensus price target of $59.10.

Bruker Trading Down 2.3%

Bruker stock traded down $0.84 during midday trading on Friday, hitting $35.50. 2,290,870 shares of the stock were exchanged, compared to its average volume of 1,628,185. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $77.61. The stock has a market capitalization of $5.38 billion, a price-to-earnings ratio of 46.71, a PEG ratio of 2.16 and a beta of 1.23. The stock's 50-day simple moving average is $39.42 and its 200 day simple moving average is $49.68. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. The business had revenue of $801.40 million during the quarter, compared to analysts' expectations of $763.83 million. During the same period last year, the business earned $0.53 earnings per share. The business's revenue for the quarter was up 11.0% on a year-over-year basis. On average, equities analysts anticipate that Bruker Co. will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Monday, June 16th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.56%. The ex-dividend date of this dividend is Monday, June 16th. Bruker's dividend payout ratio is presently 38.46%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.